Competitors
Biogen Idec's principal competitors include Teva, Sanofi Aventis, Serono, Novartis, and Bayer Schering Pharma.
As of 2004, Biogen Idec derives most of its income from sales of multiple sclerosis treatment Avonex and from partnership royalties on Rituxan from Genentech, which markets Rituxan in the US. Roche markets Rituxan outside the US as MabThera.
Read more about this topic: Biogen Idec